Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Alpelisib plus fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.18
Views: 2291

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Dr Dejan Juric speaks to ecancer at SABCS 2018 about the SOLAR-1 trial looking at alpelisib plus fulvestrant for advanced breast cancer.

He explains that line of therapy was looked into as a subgroup with the largest magnitude of effect seen in the second line setting.

Dr Juric also reports an analysis into PIK3CA mutation status in circulating tumour DNA, with PIK3CA mutant patients seeing an increased benefit.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation